Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M3,853Revenue (TTM) $M0.6Net Margin (%)-47,062.3Altman Z-Score1.9
Enterprise Value $M3,663EPS (TTM) $-7.3Operating Margin %-44,574.2Piotroski F-Score5
P/E(ttm)--Beneish M-Score--Pre-tax Margin (%)-47,062.3Higher ROA y-yY
Price/Book23.410-y EBITDA Growth Rate %--Quick Ratio5.4Cash flow > EarningsY
Price/Sales5,6035-y EBITDA Growth Rate %--Current Ratio5.5Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-87.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-169.2Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M45.9ROIC % (ttm)--Gross Margin Increase y-yY

Gurus Latest Trades with TSRO

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
TSRORon Baron 2016-03-31 Buy $32.01 - $52.32
($40.2)
$ 84.05109%New holding2,000
TSRODavid Swensen 2015-12-31 Sold Out -0.08%$40.35 - $52.91
($47.98)
$ 84.0575%Sold Out0
TSRODavid Swensen 2015-09-30 Buy 0.08%$38.97 - $65.8
($54.68)
$ 84.0554%New holding6,238
TSROLeon Cooperman 2015-06-30 Sold Out -0.05%$50.84 - $64.65
($57.38)
$ 84.0546%Sold Out0
TSROLeon Cooperman 2015-03-31 Buy 0.05%$36.62 - $61.41
($47.12)
$ 84.0578%New holding50,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

TSRO is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


TSRO: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
English Edward CVP of Finance & Administration 2016-06-10Sell7,000$40.7589.94view
Weller Harry R10% Owner 2016-03-18Buy1,420,858$35.19119.95view
Viswanathan Ravi10% Owner 2016-03-18Buy1,420,858$35.19119.95view
SANDELL SCOTT D10% Owner 2016-03-18Buy1,420,858$35.19119.95view
MOTT DAVID MDirector, 10% Owner 2016-03-18Buy1,420,858$35.19119.95view
KERINS PATRICK J10% Owner 2016-03-18Buy710,429$35.19119.95view
BASKETT FOREST10% Owner 2016-03-18Buy1,420,858$35.19119.95view
BARRIS PETER J10% Owner 2016-03-18Buy1,420,858$35.19119.95view
BARRETT M JAMES10% Owner 2016-03-18Buy710,429$35.19119.95view
NEW ENTERPRISE ASSOCIATES 13 L10% Owner 2016-03-18Buy710,429$35.19119.95view

Quarterly/Annual Reports about TSRO:

News about TSRO:

Articles On GuruFocus.com
David Swensen Bets on Antero Resources Mar 10 2016 
David Swensen's Transactions Show Diversity of Portfolio Nov 19 2015 

More From Other Websites
Tesaro cancer drug trial success Jun 29 2016
Nike, GE and PrivateBancorp climb, Esperion tumbles Jun 29 2016
Tesaro Stock Bolts On Surprise Win For Ovarian Cancer Drug Jun 29 2016
Tesaro shares more than double on positive results for ovarian cancer treatment Jun 29 2016
2 Big-Volume Stocks to Add to Your Buy List -- Plus 5 Risky Ones to Avoid Jun 29 2016
Here’s Why These Five Stocks Are On the Move on Wednesday Jun 29 2016
Biotech Gets Some Much-Needed Good News, From A Popular Target Jun 29 2016
Tesaro shares soar after positive results for ovarian cancer treatment Jun 29 2016
Tesaro's ovarian cancer drug study succeeds, shares soar Jun 29 2016
Why Tesaro Is Skyrocketing Jun 29 2016
The Brexit-battered pound is holding firm — and that bodes well for stocks Jun 29 2016
TESARO, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 29 2016
Tesaro's stock nearly doubles toward record open after successful cancer treatment trial Jun 29 2016
Tesaro's ovarian cancer drug shows benefit in late-stage trial Jun 29 2016
Myriad’s myChoice® HRD Test Successfully Identifies Patients that Meet Primary Endpoint in... Jun 29 2016
TESARO's Niraparib Significantly Improved Progression-Free Survival for Patients With Ovarian Cancer... Jun 29 2016
TESARO’s Niraparib Significantly Improved Progression-Free Survival for Patients With Ovarian... Jun 29 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)